Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 301–400 of 1,000
How I treat incidental pulmonary embolism
O'Connell, C. L. (2014) · Blood · doi:10.1182/blood-2014-08-551879 · Cited by 29
Novel oral anticoagulants: What dermatologists need to know
Plovanich, M., & Mostaghimi, A. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.11.013 · Cited by 30
Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
Watson, C. J., Zettervall, S. L., Hall, M. J., & Ganetsky, M. (2019) · Clinical Practice and Cases in Emergency Medicine · doi:10.5811/cpcem.2019.9.43650 · Cited by 30
Nagler, M., Bachmann, L. M., Schmid, P., Müller, P. R., & Wuillemin, W. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095761 · Cited by 29
“We selected six major studies, investigating the efficacy of Rivaroxaban 20 mg, Apixaban 10 mg, Warfarin or another VKA and Dabigatran 150 mg to reduce the occurrence of recurrent thromboembolism and enrolling 9,872 patients were used for the analysis [31–36].”
MethodInterference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants
Flieder, T., Weiser, M., Eller, T., Dittrich, M. T., von Bargen, K., Alban, S., Kühn, J., Knabbe, C., & Birschmann, I. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.009 · Cited by 33
Kawamatsu, N., Ishizu, T., Machino‐Ohtsuka, T., Masuda, K., Horigome, H., Takechi, F., Tateno, S., Fukuda, T., Kijima, Y., Shiina, Y., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.024 · Cited by 33
Prevention of venous thromboembolism in ambulatory patients with cancer
Khorana, A. A., Cohen, A. T., Carrier, M., Meyer, G., Pabinger, I., Kavan, P., & Wells, P. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000948 · Cited by 32
Self-citationCove, C. L., & Hylek, E. M. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000136 · Cited by 33
A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism
Comerota, A. J., & Ramacciotti, E. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.03.018 · Cited by 29
“Extended treatment is recommended for patients who have had recurrent VTE.48 The initial treatment trials evaluating dabigatran and edoxaban differed from those evaluating rivaroxaban and apixaban (Tables 2 and 3).”
BackgroundInfluentialDirect oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
Song, A. B., Rosovsky, R. P. G., Connors, J. M., & Al-Samkari, H. T. (2019) · Vascular Health and Risk Management · doi:10.2147/vhrm.s132556 · Cited by 29
Extended anticoagulation after venous thromboembolism: should it be done?
Fernandes, C. J. C. D. S., Calderaro, D., Piloto, B. M., Hoette, S., Jardim, C., & Souza, R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619878556 · Cited by 28
Huenerbein, K., Sadjadian, P., Becker, T. M., Kolatzki, V., Deventer, E., Engelhardt, C., Grießhammer, M., & Wille, K. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04350-6 · Cited by 29
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban
Jacobson‐Kelly, A. E., & Bannow, B. S. (2020) · Hematology · doi:10.1182/hematology.2020000166 · Cited by 28
Portal vein thrombosis: an overview of current treatment options
Galante, A., & Gottardi, A. D. (2021) · Acta gastro-enterologica belgica · doi:10.51821/84.2.327 · Cited by 28
Palareti, G., Poli, D., Ageno, W., Legnani, C., Antonucci, E., Bucherini, E., Testa, S., Paoletti, O., Chistolini, A., Serrao, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007973 · Cited by 30
“• Daniela Poli, Elena Lotti, Felice Crudele - Malattie Aterotrombotiche, AOU Careggi - Florence (134 recruited cases) • Walter Ageno, Alessia Abenante, Lucia Caiano, Giovanna Colombo, Matteo Guarascio – UOC Pronto Soccorso, Medicina d’Urgenza e Centro Trombosi ed Emostasi, ASST dei Sette Laghi - Varese (70) • Sophie T…”
BackgroundInfluentialHosokawa, K., Abe, K., Funakoshi, K., Tamura, Y., Nakashima, N., Todaka, K., Taniguchi, Y., Inami, T., Adachi, S., Tsujino, I., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.036 · Cited by 30
Palareti, G. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.02.002 · Cited by 29
Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach
Agnelli, G., & Becattini, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00164714 · Cited by 33
Self-citationThromboprophylaxis in Pregnancy
Kolettis, D., & Craigo, S. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2018.01.007 · Cited by 63
Harenberg, J., Du, S., Weiss, C., Krämer, R., Hoppensteadt, D., & Walenga, J. M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12547 · Cited by 29
Ageno, W., Mantovani, L. G., Haas, S. K., Kreutz, R. H., Haupt, V., Schneider, J., & Turpie, A. G. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-16 · Cited by 29
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J. E., Mismetti, P., & Goldhaber, S. Z. (2013) · Survey of Anesthesiology · doi:10.1097/01.sa.0000433313.08275.7d · Cited by 27
The new oral anticoagulants: Reasonable alternatives to warfarin
Roca, B., & Roca, M. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14052 · Cited by 28
Management of acute pulmonary embolism 2019: what is new in the updated European guidelines?
Konstantinides, S., & Meyer, G. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02340-0 · Cited by 34
“) should be considered after 6 months of therapeutic anticoagulation [36, 37].”
BackgroundAnticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?
Weitz, J. I., Prandoni, P., & Verhamme, P. B. (2020) · TH Open · doi:10.1055/s-0040-1721735 · Cited by 35
Self-citationSuccinct Review of the New VTE Prevention and Management Guidelines
Pollak, A. W., & McBane, R. D. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.015 · Cited by 28
Novel Oral Anticoagulants in Cardiovascular Disease
Gallego, P., Roldán, V., & Lip, G. Y. H. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501392 · Cited by 29
Platelets as Central Actors in Thrombosis—Reprising an Old Role and Defining a New Character
Stevens, H., & McFadyen, J. D. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1698829 · Cited by 31
Fifty years of research on antithrombotic therapy: Achievements and disappointments
Hirsh, J., Eikelboom, J. W., & Chan, N. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.023 · Cited by 29
Sulaiman, K. A. A., Hafiz, A. M., Badreldin, H. A., Korayem, G. B., Alsuwayyid, F., Alrashidi, A., Alhijris, M., Almutairi, F. F., Alharthi, F., Alghamdi, S. A., et al. (2022) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096221099893 · Cited by 26
Raggam, R. B., Hafner, F., Avian, A., Hackl, G., Cvirn, G., Brodmann, M., Gary, T., & Rief, P. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607433 · Cited by 29
Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence
Bracey, A., Shatila, W., & Wilson, J. M. (2018) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944718801554 · Cited by 31
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Blood · doi:10.1182/blood-2018-05-848697 · Cited by 27
Kim, K., Yamashita, Y., Morimoto, T., Kitai, T., Yamane, T., Ehara, N., Kinoshita, M., Kaji, S., Amano, H., Takase, T., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692425 · Cited by 28
How, J., Story, C. M., Ren, S., Neuberg, D. S., Rosovsky, R. P. G., Hobbs, G. S., & Connors, J. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00566-5 · Cited by 27
“A minority of patients were decreased to prophylactic dosing for secondary VTE prevention after a median of 21 months, similar to the protocol seen in the AMPLIFY-EXTEND and EINSTEIN-CHOICE studies, although this has not yet been studied specifically in MPN patients [24, 25].”
ResultDirect oral anticoagulants for use in paediatrics
Jaffray, J., & Young, G. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00343-6 · Cited by 29
Gómez‐Outes, A., Suárez-Gea, Lecumberri, R., Terleira‐Fernández, A. I., Vargas, E., & Rocha (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s35843 · Cited by 28
“15 Some studies with the new anticoagulants have assessed the issue of extending VTE treatment beyond 3–6 months in comparison with warfarin 105 or placebo, 61,76,105 but the percentage of patients with cancer included in these studies is very limited and further specific studies are needed.”
InfluentialPiazza, G. (2015) · Vascular Medicine · doi:10.1177/1358863x14568706 · Cited by 30
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
Diagnose und Management der akuten pulmonalen Embolie: ESC-Leitlinien 2014
Saar, J. A., & Maack, C. (2015) · Herz · doi:10.1007/s00059-015-4378-0 · Cited by 30
van Es, N., Wells, P. S., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.02.016 · Cited by 32
Bertoletti, L., Benhamou, Y., Béjot, Y., Maréchaux, S., Cheggour, S., Aleil, B., Lellouche, N., Dillinger, J., & Delluc, A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.01.002 · Cited by 30
Russo, A. V., Curtis, S. A., Balbuena-Merle, R. I., Wadia, R. J., Wong, E. Y.-M., & Chao, H. H. (2018) · Experimental Hematology and Oncology · doi:10.1186/s40164-018-0108-7 · Cited by 26
Diseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
Weitz, J. I., & Jaffer, I. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3547 · Cited by 28
Self-citationRecent developments in the diagnosis and treatment of pulmonary embolism
van der Hulle, T., Dronkers, C. E. A., Klok, F. A., & Huisman, M. V. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12404 · Cited by 28
Long, B., & Koyfman, A. (2016) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.08.021 · Cited by 27
New Trends in Anticoagulation Therapy
SMITH, M. H. D., Wakam, G. K., Wakefield, T. W., & Obi, A. T. (2018) · Surgical Clinics of North America · doi:10.1016/j.suc.2017.11.003 · Cited by 26
“(46, 47) While evidence exists that lower dose anticoagulants may effectively reduce VTE recurrence, the most effective therapy with the safest treatment profile and lowest cost is still being debated.”
BackgroundCoulis, A. A., & Mackey, W. C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.009 · Cited by 27
Sasso, R., & Rockey, D. C. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.006 · Cited by 25
Recio‐Boiles, A., Veeravelli, S., Vondrak, J., Babiker, H. M., Scott, A. J., Shroff, R. T., Patel, H., Elquza, E., & McBride, A. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i10.866 · Cited by 25
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation
Jaffer, I., Fredenburgh, J. C., Stafford, A. R., Whitlock, R. P., & Weitz, J. I. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.10.091 · Cited by 26
Self-citationTreatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
Bavalia, R., Middeldorp, S., Weißer, G., & Espinola–Klein, C. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1710314 · Cited by 26
Booth, S. W., The HaemSTAR Network, Desborough, M., Curry, N. S., Stanworth, S. J., Janum, S., Todd, S., Bull, T., Dunne, M., Abeyrathna, S. P., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15748 · Cited by 25
Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation
Højen, A. A., Nielsen, P. B., Overvad, T. F., Albertsen, I. E., Klok, F. A., Rolving, N., Søgaard, M., & Ording, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195970 · Cited by 32
“Apixaban AMPLIFY Extension, 2013 [37] Placebo vs.”
BackgroundAmin, A., & Marrs, J. C. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615601492 · Cited by 28
“Nevertheless, all direct OACs have demonstrated efficacy and safety in clinical trials regardless of whether dosed od or twice daily.(26,27,29-36,38,39)”
BackgroundResultCastellucci, L. A., Gal, G. L., Rodger, M. A., & Carrier, M. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12501 · Cited by 27
Novel anticoagulants and antiplatelet agents; a guide for the urologist
Ellis, G., Camm, A. J., & Datta, S. N. (2015) · British Journal of Urology · doi:10.1111/bju.13131 · Cited by 26
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
Agnelli, G., & Becattini, C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.471 · Cited by 27
Self-citationIbrutinib-related bleeding: pathogenesis, clinical implications and management
Aguilar, C. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000749 · Cited by 26
Liu, J., Pei, W., Yan, Y., & Kui, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58345-4 · Cited by 27
Zhu, H., Zheng, H., Xu, T., Liu, X., Liu, X., Sun, L., Pan, X., Mai, W., Cai, X., & Huang, Y. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106931 · Cited by 25
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020230 · Cited by 28
Mandt, S. R., Thadathil, N., Klem, C., Russ, C., McNamee, P. L., Stigge, K., & Cheng, D. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00664-2 · Cited by 28
“…prevention of recurrent VTE, and included patients with varying levels of kidney impairment, are AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) [27] and AMPLIFY-EXT (Apixaban for Extended Treatment of Venous Thrombo-embolism) [28].”
InfluentialCurrent Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
“After PE diagnosis, the optimal duration of treatment has been explored in four randomized clinical trials focusing on dabigatran [99], rivaroxaban [110], apixaban [111], and edoxaban [102].”
BackgroundResultTreatment options for venous thromboembolism: lessons learnt from clinical trials
McRae, S. J. (2014) · Thrombosis Journal · doi:10.1186/s12959-014-0027-8 · Cited by 26
Pharmacology and Laboratory Testing of the Oral Xa Inhibitors
Samama, M. M., Meddahi, S., & Samama, C. M. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.009 · Cited by 26
Wysokiński, W. E., Froehling, D. A., Houghton, D. E., McBane, R. D., Vlazny, D. T., Bott‐Kitslaar, D. M., Kuczmik, W., Sutkowska, K., Bator, K., Hodge, D. O., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13471 · Cited by 25
Frei, A. N., Stalder, O., Limacher, A., Méan, M., Baumgartner, C., Rodondi, N., & Aujesky, D. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1726345 · Cited by 27
Submassive Pulmonary Embolism: Current Perspectives and Future Directions
Nguyen, P., Stevens, H., Peter, K., & McFadyen, J. D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153383 · Cited by 26
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
Liu, A., Naymagon, L., & Tremblay, D. A. (2022) · Cancers · doi:10.3390/cancers15010011 · Cited by 24
The newer direct oral anticoagulants: a practical guide
Thachil, J. V. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-2-165 · Cited by 25
Developments in the management and treatment of pulmonary embolism
Limbrey, R., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.00006614 · Cited by 28
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
Racial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 25
Áinle, F. N., & Kevane, B. (2020) · Hematology · doi:10.1182/hematology.2020002268 · Cited by 27
“Cosmi et al 2010 (52) Prospective multicenter study (first unprovoked VTE) N/R D-dimer 1 mo after D/C AC Persistently abnormal D-dimer: 27%/person-years (12-48)”
BackgroundA review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
Lanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
Self-citationNew oral anticoagulants for the treatment of venous thromboembolism
Agnelli, G., Becattini, C., & Franco, L. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.005 · Cited by 23
Self-citationDobesh, P. P., & Fanikos, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0301-x · Cited by 24
“Outcome RE-MEDY [30] RE-SONATE [30] EINSTEIN-Extension [16] AMPLIFY-EXT [28]”
BackgroundResultInfluentialBarbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
“The results of the AMPLIFY-Extension study suggest that halving the initial dose after the first 6 months in patients with unprovoked VTE is likely to preserve protection against recurrent VTE while further reducing the haemorrhagic risk (67).”
BackgroundMethodGeersing, G., Hendriksen, J. M. T., Zuithoff, N. P. A., Roes, K. C. B., Oudega, R., Takada, T., Schutgens, R. E. G., & Moons, K. G. M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003142 · Cited by 24
“25 for prolonged anticoagulant treatment (compared to placebo [18,19]), we can estimate the number of recurrent VTE events for different treatment strategies over a time period of 5 years.”
BackgroundBranstetter, J. W., Kiskaddon, A. L., King, M. A., Coalter, C., Grubbs, K. M., Fly, J. H., Male, C., Brandão, L. R., & Goldenberg, N. A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1725944 · Cited by 23
Changing Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Apixaban: A Review in Venous Thromboembolism
Greig, S. L., & Garnock-Jones, K. P. (2016) · Drugs · doi:10.1007/s40265-016-0644-6 · Cited by 26
“AMPLIFY and AMPLIFY-J were active comparatorcontrolled trials that enrolled patients with objectively confirmed, acute, symptomatic VTE [32, 34], and AMPLIFY-EXT was a placebo-controlled trial that included patients who had completed 6–12 months’ treatment with standard anticoagulant therapy for objectively confirmed,…”
BackgroundMethodInfluentialde Jong, L. A., Dvortsin, E., Janssen, K. J. M., & Postma, M. J. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.012 · Cited by 23
“292 assumed to be equal across treatments.(8,9) After treatment cessation, lifetime risk of RecVTE was calculated from the cumulative 10-year incidence at 39.”
BackgroundMethodInfluentialThe effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Frost, C. E., Song, Y. J., Yu, Z., Wang, J. J. J., Lee, L., Schuster, A. E., Pollack, A., & LaCreta, F. P. (2017) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s115687 · Cited by 27
Bartoli-Abdou, J., Patel, J. P., Crawshaw, J., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.021 · Cited by 24
Lee, J. H., Hyun, D., Choi, C., Lee, J. C., Kim, W. S., Oh, Y., Lee, S., & Lee, J. S. (2019) · Respiration · doi:10.1159/000499895 · Cited by 23
Korobey, M. J., Sadaka, F. G., Javed, M. A., Moynihan, M., & Alsaei, A. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00968-6 · Cited by 23
Bleeding and clotting in hereditary hemorrhagic telangiectasia
Dittus, C. E., Streiff, M., & Ansell, J. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i4.330 · Cited by 25
Sindet-Pedersen, C., Pallisgaard, J. L., Olesen, J. B., Gislason, G. H., & Arevalo, L. C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.022 · Cited by 22
“The duration of oral anticoagulation treatment is based on the individual patient ́s risk of bleeding and risk of a recurrent VTE [7] and patients with unprovoked VTE are usually recommended treatment for 3–6 months with oral anticoagulants [4,8].”
BackgroundMethodResultInfluentialManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 24
“Patients on dual antiplatelet or daily low-dose aspirin were excluded from the AMPLIFY program.(38,48) Therefore, the impact of these agents on the efficacy and safety of the DOACs in VTE treatment has not yet been determined.”
InfluentialBroadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Self-citationPuy, L., Forman, R., Cordonnier, C., & Sheth, K. N. (2022) · Stroke · doi:10.1161/strokeaha.122.036888 · Cited by 25
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Linnemann, B., Beyer‐Westendorf, J., Espinola–Klein, C., Mühlberg, K. S., Müller, O. J., & Klamroth, R. (2024) · Hämostaseologie · doi:10.1055/a-2178-6574 · Cited by 32
Diagnosis and treatment of acute pulmonary embolism
Widimsky, J., Jr. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.10.001 · Cited by 22
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Ceresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 25
“The results of key studies of each of the DOACs are summarized in Table 2 (64-71).”
Background
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.